Clinical Trials Logo
  1. Home
  2. Seasonal Influenza
  3. NCT00498303
  4. Details
NCT00498303 Clinical Trial

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008

Seasonal Influenza Clinical Trial

Official title:
A Phase III, Multicenter, Uncontrolled, Open-Label Study to Evaluate Safety and Immunogenicity of Preservative Free, Inactivated Split Influenza Vaccine, Using the Strain Composition 2007/2008 When Administered to Adult and Elderly Subjects

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00498303
Other study ID # V44P11S
Secondary ID 2007-001403-38
Status Completed
Phase Phase 3
First received July 9, 2007
Last updated April 21, 2008
Start date June 2007

Study information
Verified date April 2008
Source Novartis
Contact n/a
Is FDA regulated No
Health authority Germany: Paul-Ehrlich-Institute
Study type Interventional

Clinical Trial Summary

Annual trial for registration of trivalent split influenza vaccine with the strain composition of the season 2007/2008 in healthy adult and elderly subjects

Recruitment information / eligibility
Status Completed
Enrollment 120
Est. completion date
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- = 18 years of age, mentally competent, willing and able to give informed consent prior to study entry

- available for all the visits scheduled in the study and able to comply with all study requirements

- in good health as determined by: medical history, physical examination, clinical judgment of the investigator

Exclusion Criteria:

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Intervention

Biological:
• trivalent split influenza vaccine

Locations
Country Name City State
Germany Werksarztzentrum Herborn Herborn

Sponsors (2)
Lead Sponsor Collaborator
Novartis Novartis Vaccines

Country where clinical trial is conducted

Germany, 

Outcome
Type Measure Description Time frame Safety issue
Primary evaluate the antibody response to each influenza vaccine antigen, as measured by haemagglutination inhibition (HI) test on Day 0 and on Day 21
Primary evaluate safety of trivalent split influenza vaccine
See also
  Status Clinical Trial Phase
Completed NCT01209780 - Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age Phase 3
Completed NCT01180621 - Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children Phase 2
Completed NCT01206686 - The Effect of Time-Slot Scheduling on Flu Vaccination Rates N/A
Recruiting NCT06049927 - A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months Phase 3
Completed NCT04133584 - The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine Phase 4
Completed NCT05566639 - A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older Phase 3
Completed NCT01207232 - The Effect of a Planning Prompt on Seasonal Influenza Vaccination Rates N/A
Completed NCT01072799 - Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine Phase 2
Completed NCT00957996 - Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza Phase 3
Completed NCT04997239 - A Clinical Trial of Quadrivalent Influenza Vaccine in Children Aged 3-8 Years Old Phase 4
Completed NCT05512494 - Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated Phase 4
Terminated NCT00958776 - A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza Phase 3
Completed NCT01011582 - Characteristics and Outcomes of Intensive Care Unit Patients Admitted With Novel H1N1 Influenza or Seasonal Influenza N/A
Completed NCT00560066 - Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions Phase 4
Active, not recruiting NCT05397223 - A Study of Modified mRNA Vaccines in Healthy Adults Phase 1
Completed NCT04896086 - First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV, in Healthy Adults Phase 1
Completed NCT01344057 - Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012 Phase 2
Completed NCT01342796 - Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects Phase 2
Completed NCT00903552 - Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) Phase 2
Completed NCT05827068 - A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults Phase 1/Phase 2